Instructors for this course:
Ronjon Nag, PhD
Adjunct Professor in Genetics, Stanford School of Medicine
Director, R42 Longevity Fund
Longevity covers therapeutics, robotics, and fintech. Yet as an emerging industry how do these get financed when they are so risky?
How should venture firms evaluate longevity companies and how should founders attract investors and employees?
- This course will look at these questions specifically as applied to longevity, uniquely from the investor, scientist, and the founder viewpoint.
- After providing a foundation to the field we will interact with guest lectures from investors, scientists and company founders who can explain their respective perspectives.
- The course will cover finance and science aspects of longevity though no pre-requisites are expected.
Winter 2021 Papers
Proteomics and Proteomics Companies for Aging Research
The Key to Longevity : Don’t Die
Longevity Venture Capital Venture Opportunities for the Aging Brain
Ryan Leonard Pei
Zhan-Qiu (Austin) Liu
Shreyas P. Parab
Patrick T. Tjandra
Sarah Lea Tobocman